First Time Loading...

Celldex Therapeutics Inc
NASDAQ:CLDX

Watchlist Manager
Celldex Therapeutics Inc Logo
Celldex Therapeutics Inc
NASDAQ:CLDX
Watchlist
Price: 40.86 USD 3.84%
Updated: May 3, 2024

Celldex Therapeutics Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Celldex Therapeutics Inc
Cash from Operating Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Celldex Therapeutics Inc
NASDAQ:CLDX
Cash from Operating Activities
-$107.3m
CAGR 3-Years
-38%
CAGR 5-Years
-7%
CAGR 10-Years
-5%
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$22.8B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
14%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$8B
CAGR 3-Years
-5%
CAGR 5-Years
1%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$8.5B
CAGR 3-Years
-7%
CAGR 5-Years
-6%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.5B
CAGR 3-Years
3%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.6B
CAGR 3-Years
21%
CAGR 5-Years
16%
CAGR 10-Years
23%

See Also

What is Celldex Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-107.3m USD

Based on the financial report for Dec 31, 2023, Celldex Therapeutics Inc's Cash from Operating Activities amounts to -107.3m USD.

What is Celldex Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-5%

Over the last year, the Cash from Operating Activities growth was -3%. The average annual Cash from Operating Activities growth rates for Celldex Therapeutics Inc have been -38% over the past three years , -7% over the past five years , and -5% over the past ten years .